These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses]. Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589 [TBL] [Abstract][Full Text] [Related]
9. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042 [TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [TBL] [Abstract][Full Text] [Related]
11. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Lazarus HM; Herzig RH; Herzig GP; Phillips GL; Roessmann U; Fishman DJ Cancer; 1981 Dec; 48(12):2577-82. PubMed ID: 7306918 [TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group. Lazarus HM; Vogler WR; Burns CP; Winton EF Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia]. Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Grant S; Baker M; Bhalla K Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091 [TBL] [Abstract][Full Text] [Related]
16. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia]. Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405 [TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890 [TBL] [Abstract][Full Text] [Related]
18. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588 [TBL] [Abstract][Full Text] [Related]
19. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich EJ Leukemia; 1987 Aug; 1(8):580-3. PubMed ID: 3669771 [TBL] [Abstract][Full Text] [Related]